April 2026 Issue

In this issue, Ravi Ganapathy (IVI) offers a comprehensive look at continuous vaccine manufacturing, mapping the bottlenecks, technologies, and regulatory considerations shaping the field. Plus, contributors from CEPI, the IVI Europe Regional Office, and the Novo Nordisk Foundation for Vaccines & Immunity make the case for a formalised Nordic vaccine collaboration.

"Preparedness cannot be built during a crisis, and existing Nordic capabilities should be harmonised during peacetime." – Catherine Fleck-Vidal, International Vaccine Institute Europe Regional Office

"The industry's shift toward process intensification represents not only a technological advancement but also a fundamental transformation in vaccine manufacturing practices – from distinct batch processes to interconnected, data-driven, continuous systems." – Ravi Ganapathy, Senior Director of Vaccine Process Development, IVI